 | • レポートコード：MRC2-11QY04199 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、97ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料はPEG化タンパク質治療薬のグローバル市場について調査・分析したレポートです。種類別（コロニー刺激因子、インターフェロン、エリスロポエチン（EPO）、組換え因子VIII、モノクローナル抗体、酵素、その他）市場規模、用途別（がん、自己免疫疾患、肝炎、多発性硬化症、血友病、胃腸障害、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別PEG化タンパク質治療薬の競争状況、市場シェア ・世界のPEG化タンパク質治療薬市場：種類別市場規模 2015年-2020年（コロニー刺激因子、インターフェロン、エリスロポエチン（EPO）、組換え因子VIII、モノクローナル抗体、酵素、その他） ・世界のPEG化タンパク質治療薬市場：種類別市場規模予測 2021年-2026年（コロニー刺激因子、インターフェロン、エリスロポエチン（EPO）、組換え因子VIII、モノクローナル抗体、酵素、その他） ・世界のPEG化タンパク質治療薬市場：用途別市場規模 2015年-2020年（がん、自己免疫疾患、肝炎、多発性硬化症、血友病、胃腸障害、その他） ・世界のPEG化タンパク質治療薬市場：用途別市場規模予測 2021年-2026年（がん、自己免疫疾患、肝炎、多発性硬化症、血友病、胃腸障害、その他） ・北米のPEG化タンパク質治療薬市場分析：米国、カナダ ・ヨーロッパのPEG化タンパク質治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアのPEG化タンパク質治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米のPEG化タンパク質治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカのPEG化タンパク質治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Merck、Pfizer、UCB、Amgen、AstraZeneca、Biogen、Roche、Horizon Pharma、Leadiant Biosciences ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
PEGylation is the process of covalent and non-covalent attachment of polyethylene glycol polymer chains to molecules, such as a drug, therapeutic protein, or vesicle. PEGylated protein therapeutics is estimated to show significant market growth during the forecast period, majorly due to the, growth in demand for PEGylation, rise in number of chronic diseases, and presence of strong pipeline drugs.
Higher process cost associated with PEGylation and patent expiry of certain drugs are projected to hinder the market growth.
Market Analysis and Insights: Global PEGylated Protein Therapeutics Market
The global PEGylated Protein Therapeutics market size is projected to reach US$ 10140 million by 2026, from US$ 9730.2 million in 2020, at a CAGR of 3.9%% during 2021-2026.
Global PEGylated Protein Therapeutics Scope and Market Size
PEGylated Protein Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global PEGylated Protein Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Merck
Pfizer
UCB
Amgen
AstraZeneca
Biogen
Roche
Horizon Pharma
Leadiant Biosciences
Market segment by Type, the product can be split into
Colony Stimulating Factor
Interferon
Erythropoietin (EPO)
Recombinant Factor VIII
Monoclonal Antibody
Enzyme
Others
Market segment by Application, split into
Cancer
Autoimmune Disease
Hepatitis
Multiple Sclerosis
Hemophilia
Gastrointestinal Disorder
Others
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by PEGylated Protein Therapeutics Revenue
1.4 Market by Type
1.4.1 Global PEGylated Protein Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Colony Stimulating Factor
1.4.3 Interferon
1.4.4 Erythropoietin (EPO)
1.4.5 Recombinant Factor VIII
1.4.6 Monoclonal Antibody
1.4.7 Enzyme
1.4.8 Others
1.5 Market by Application
1.5.1 Global PEGylated Protein Therapeutics Market Share by Application: 2020 VS 2026
1.5.2 Cancer
1.5.3 Autoimmune Disease
1.5.4 Hepatitis
1.5.5 Multiple Sclerosis
1.5.6 Hemophilia
1.5.7 Gastrointestinal Disorder
1.5.8 Others
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global PEGylated Protein Therapeutics Market Perspective (2015-2026)
2.2 Global PEGylated Protein Therapeutics Growth Trends by Regions
2.2.1 PEGylated Protein Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 PEGylated Protein Therapeutics Historic Market Share by Regions (2015-2020)
2.2.3 PEGylated Protein Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 PEGylated Protein Therapeutics Market Growth Strategy
2.3.6 Primary Interviews with Key PEGylated Protein Therapeutics Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top PEGylated Protein Therapeutics Players by Market Size
3.1.1 Global Top PEGylated Protein Therapeutics Players by Revenue (2015-2020)
3.1.2 Global PEGylated Protein Therapeutics Revenue Market Share by Players (2015-2020)
3.1.3 Global PEGylated Protein Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global PEGylated Protein Therapeutics Market Concentration Ratio
3.2.1 Global PEGylated Protein Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by PEGylated Protein Therapeutics Revenue in 2019
3.3 PEGylated Protein Therapeutics Key Players Head office and Area Served
3.4 Key Players PEGylated Protein Therapeutics Product Solution and Service
3.5 Date of Enter into PEGylated Protein Therapeutics Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global PEGylated Protein Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global PEGylated Protein Therapeutics Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global PEGylated Protein Therapeutics Market Size by Application (2015-2020)
5.2 Global PEGylated Protein Therapeutics Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America PEGylated Protein Therapeutics Market Size (2015-2020)
6.2 PEGylated Protein Therapeutics Key Players in North America (2019-2020)
6.3 North America PEGylated Protein Therapeutics Market Size by Type (2015-2020)
6.4 North America PEGylated Protein Therapeutics Market Size by Application (2015-2020)
7 Europe
7.1 Europe PEGylated Protein Therapeutics Market Size (2015-2020)
7.2 PEGylated Protein Therapeutics Key Players in Europe (2019-2020)
7.3 Europe PEGylated Protein Therapeutics Market Size by Type (2015-2020)
7.4 Europe PEGylated Protein Therapeutics Market Size by Application (2015-2020)
8 China
8.1 China PEGylated Protein Therapeutics Market Size (2015-2020)
8.2 PEGylated Protein Therapeutics Key Players in China (2019-2020)
8.3 China PEGylated Protein Therapeutics Market Size by Type (2015-2020)
8.4 China PEGylated Protein Therapeutics Market Size by Application (2015-2020)
9 Japan
9.1 Japan PEGylated Protein Therapeutics Market Size (2015-2020)
9.2 PEGylated Protein Therapeutics Key Players in Japan (2019-2020)
9.3 Japan PEGylated Protein Therapeutics Market Size by Type (2015-2020)
9.4 Japan PEGylated Protein Therapeutics Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia PEGylated Protein Therapeutics Market Size (2015-2020)
10.2 PEGylated Protein Therapeutics Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia PEGylated Protein Therapeutics Market Size by Type (2015-2020)
10.4 Southeast Asia PEGylated Protein Therapeutics Market Size by Application (2015-2020)
11 India
11.1 India PEGylated Protein Therapeutics Market Size (2015-2020)
11.2 PEGylated Protein Therapeutics Key Players in India (2019-2020)
11.3 India PEGylated Protein Therapeutics Market Size by Type (2015-2020)
11.4 India PEGylated Protein Therapeutics Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America PEGylated Protein Therapeutics Market Size (2015-2020)
12.2 PEGylated Protein Therapeutics Key Players in Central & South America (2019-2020)
12.3 Central & South America PEGylated Protein Therapeutics Market Size by Type (2015-2020)
12.4 Central & South America PEGylated Protein Therapeutics Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Merck
13.1.1 Merck Company Details
13.1.2 Merck Business Overview
13.1.3 Merck PEGylated Protein Therapeutics Introduction
13.1.4 Merck Revenue in PEGylated Protein Therapeutics Business (2015-2020))
13.1.5 Merck Recent Development
13.2 Pfizer
13.2.1 Pfizer Company Details
13.2.2 Pfizer Business Overview
13.2.3 Pfizer PEGylated Protein Therapeutics Introduction
13.2.4 Pfizer Revenue in PEGylated Protein Therapeutics Business (2015-2020)
13.2.5 Pfizer Recent Development
13.3 UCB
13.3.1 UCB Company Details
13.3.2 UCB Business Overview
13.3.3 UCB PEGylated Protein Therapeutics Introduction
13.3.4 UCB Revenue in PEGylated Protein Therapeutics Business (2015-2020)
13.3.5 UCB Recent Development
13.4 Amgen
13.4.1 Amgen Company Details
13.4.2 Amgen Business Overview
13.4.3 Amgen PEGylated Protein Therapeutics Introduction
13.4.4 Amgen Revenue in PEGylated Protein Therapeutics Business (2015-2020)
13.4.5 Amgen Recent Development
13.5 AstraZeneca
13.5.1 AstraZeneca Company Details
13.5.2 AstraZeneca Business Overview
13.5.3 AstraZeneca PEGylated Protein Therapeutics Introduction
13.5.4 AstraZeneca Revenue in PEGylated Protein Therapeutics Business (2015-2020)
13.5.5 AstraZeneca Recent Development
13.6 Biogen
13.6.1 Biogen Company Details
13.6.2 Biogen Business Overview
13.6.3 Biogen PEGylated Protein Therapeutics Introduction
13.6.4 Biogen Revenue in PEGylated Protein Therapeutics Business (2015-2020)
13.6.5 Biogen Recent Development
13.7 Roche
13.7.1 Roche Company Details
13.7.2 Roche Business Overview
13.7.3 Roche PEGylated Protein Therapeutics Introduction
13.7.4 Roche Revenue in PEGylated Protein Therapeutics Business (2015-2020)
13.7.5 Roche Recent Development
13.8 Horizon Pharma
13.8.1 Horizon Pharma Company Details
13.8.2 Horizon Pharma Business Overview
13.8.3 Horizon Pharma PEGylated Protein Therapeutics Introduction
13.8.4 Horizon Pharma Revenue in PEGylated Protein Therapeutics Business (2015-2020)
13.8.5 Horizon Pharma Recent Development
13.9 Leadiant Biosciences
13.9.1 Leadiant Biosciences Company Details
13.9.2 Leadiant Biosciences Business Overview
13.9.3 Leadiant Biosciences PEGylated Protein Therapeutics Introduction
13.9.4 Leadiant Biosciences Revenue in PEGylated Protein Therapeutics Business (2015-2020)
13.9.5 Leadiant Biosciences Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. PEGylated Protein Therapeutics Key Market Segments
Table 2. Key Players Covered: Ranking by PEGylated Protein Therapeutics Revenue
Table 3. Ranking of Global Top PEGylated Protein Therapeutics Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global PEGylated Protein Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Colony Stimulating Factor
Table 6. Key Players of Interferon
Table 7. Key Players of Erythropoietin (EPO)
Table 8. Key Players of Recombinant Factor VIII
Table 9. Key Players of Monoclonal Antibody
Table 10. Key Players of Enzyme
Table 11. Key Players of Others
Table 12. Global PEGylated Protein Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 13. Global PEGylated Protein Therapeutics Market Size by Regions (US$ Million): 2020 VS 2026
Table 14. Global PEGylated Protein Therapeutics Market Size by Regions (2015-2020) (US$ Million)
Table 15. Global PEGylated Protein Therapeutics Market Share by Regions (2015-2020)
Table 16. Global PEGylated Protein Therapeutics Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 17. Global PEGylated Protein Therapeutics Market Share by Regions (2021-2026)
Table 18. Market Top Trends
Table 19. Key Drivers: Impact Analysis
Table 20. Key Challenges
Table 21. PEGylated Protein Therapeutics Market Growth Strategy
Table 22. Main Points Interviewed from Key PEGylated Protein Therapeutics Players
Table 23. Global PEGylated Protein Therapeutics Revenue by Players (2015-2020) (Million US$)
Table 24. Global PEGylated Protein Therapeutics Market Share by Players (2015-2020)
Table 25. Global Top PEGylated Protein Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in PEGylated Protein Therapeutics as of 2019)
Table 26. Global PEGylated Protein Therapeutics by Players Market Concentration Ratio (CR5 and HHI)
Table 27. Key Players Headquarters and Area Served
Table 28. Key Players PEGylated Protein Therapeutics Product Solution and Service
Table 29. Date of Enter into PEGylated Protein Therapeutics Market
Table 30. Mergers & Acquisitions, Expansion Plans
Table 31. Global PEGylated Protein Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 32. Global PEGylated Protein Therapeutics Market Size Share by Type (2015-2020)
Table 33. Global PEGylated Protein Therapeutics Revenue Market Share by Type (2021-2026)
Table 34. Global PEGylated Protein Therapeutics Market Size Share by Application (2015-2020)
Table 35. Global PEGylated Protein Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 36. Global PEGylated Protein Therapeutics Market Size Share by Application (2021-2026)
Table 37. North America Key Players PEGylated Protein Therapeutics Revenue (2019-2020) (Million US$)
Table 38. North America Key Players PEGylated Protein Therapeutics Market Share (2019-2020)
Table 39. North America PEGylated Protein Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 40. North America PEGylated Protein Therapeutics Market Share by Type (2015-2020)
Table 41. North America PEGylated Protein Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 42. North America PEGylated Protein Therapeutics Market Share by Application (2015-2020)
Table 43. Europe Key Players PEGylated Protein Therapeutics Revenue (2019-2020) (Million US$)
Table 44. Europe Key Players PEGylated Protein Therapeutics Market Share (2019-2020)
Table 45. Europe PEGylated Protein Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 46. Europe PEGylated Protein Therapeutics Market Share by Type (2015-2020)
Table 47. Europe PEGylated Protein Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 48. Europe PEGylated Protein Therapeutics Market Share by Application (2015-2020)
Table 49. China Key Players PEGylated Protein Therapeutics Revenue (2019-2020) (Million US$)
Table 50. China Key Players PEGylated Protein Therapeutics Market Share (2019-2020)
Table 51. China PEGylated Protein Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 52. China PEGylated Protein Therapeutics Market Share by Type (2015-2020)
Table 53. China PEGylated Protein Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 54. China PEGylated Protein Therapeutics Market Share by Application (2015-2020)
Table 55. Japan Key Players PEGylated Protein Therapeutics Revenue (2019-2020) (Million US$)
Table 56. Japan Key Players PEGylated Protein Therapeutics Market Share (2019-2020)
Table 57. Japan PEGylated Protein Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 58. Japan PEGylated Protein Therapeutics Market Share by Type (2015-2020)
Table 59. Japan PEGylated Protein Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 60. Japan PEGylated Protein Therapeutics Market Share by Application (2015-2020)
Table 61. Southeast Asia Key Players PEGylated Protein Therapeutics Revenue (2019-2020) (Million US$)
Table 62. Southeast Asia Key Players PEGylated Protein Therapeutics Market Share (2019-2020)
Table 63. Southeast Asia PEGylated Protein Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 64. Southeast Asia PEGylated Protein Therapeutics Market Share by Type (2015-2020)
Table 65. Southeast Asia PEGylated Protein Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 66. Southeast Asia PEGylated Protein Therapeutics Market Share by Application (2015-2020)
Table 67. India Key Players PEGylated Protein Therapeutics Revenue (2019-2020) (Million US$)
Table 68. India Key Players PEGylated Protein Therapeutics Market Share (2019-2020)
Table 69. India PEGylated Protein Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 70. India PEGylated Protein Therapeutics Market Share by Type (2015-2020)
Table 71. India PEGylated Protein Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 72. India PEGylated Protein Therapeutics Market Share by Application (2015-2020)
Table 73. Central & South America Key Players PEGylated Protein Therapeutics Revenue (2019-2020) (Million US$)
Table 74. Central & South America Key Players PEGylated Protein Therapeutics Market Share (2019-2020)
Table 75. Central & South America PEGylated Protein Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 76. Central & South America PEGylated Protein Therapeutics Market Share by Type (2015-2020)
Table 77. Central & South America PEGylated Protein Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 78. Central & South America PEGylated Protein Therapeutics Market Share by Application (2015-2020)
Table 79. Merck Company Details
Table 80. Merck Business Overview
Table 81. Merck Product
Table 82. Merck Revenue in PEGylated Protein Therapeutics Business (2015-2020) (Million US$)
Table 83. Merck Recent Development
Table 84. Pfizer Company Details
Table 85. Pfizer Business Overview
Table 86. Pfizer Product
Table 87. Pfizer Revenue in PEGylated Protein Therapeutics Business (2015-2020) (Million US$)
Table 88. Pfizer Recent Development
Table 89. UCB Company Details
Table 90. UCB Business Overview
Table 91. UCB Product
Table 92. UCB Revenue in PEGylated Protein Therapeutics Business (2015-2020) (Million US$)
Table 93. UCB Recent Development
Table 94. Amgen Company Details
Table 95. Amgen Business Overview
Table 96. Amgen Product
Table 97. Amgen Revenue in PEGylated Protein Therapeutics Business (2015-2020) (Million US$)
Table 98. Amgen Recent Development
Table 99. AstraZeneca Company Details
Table 100. AstraZeneca Business Overview
Table 101. AstraZeneca Product
Table 102. AstraZeneca Revenue in PEGylated Protein Therapeutics Business (2015-2020) (Million US$)
Table 103. AstraZeneca Recent Development
Table 104. Biogen Company Details
Table 105. Biogen Business Overview
Table 106. Biogen Product
Table 107. Biogen Revenue in PEGylated Protein Therapeutics Business (2015-2020) (Million US$)
Table 108. Biogen Recent Development
Table 109. Roche Company Details
Table 110. Roche Business Overview
Table 111. Roche Product
Table 112. Roche Revenue in PEGylated Protein Therapeutics Business (2015-2020) (Million US$)
Table 113. Roche Recent Development
Table 114. Horizon Pharma Business Overview
Table 115. Horizon Pharma Product
Table 116. Horizon Pharma Company Details
Table 117. Horizon Pharma Revenue in PEGylated Protein Therapeutics Business (2015-2020) (Million US$)
Table 118. Horizon Pharma Recent Development
Table 119. Leadiant Biosciences Company Details
Table 120. Leadiant Biosciences Business Overview
Table 121. Leadiant Biosciences Product
Table 122. Leadiant Biosciences Revenue in PEGylated Protein Therapeutics Business (2015-2020) (Million US$)
Table 123. Leadiant Biosciences Recent Development
Table 124. Research Programs/Design for This Report
Table 125. Key Data Information from Secondary Sources
Table 126. Key Data Information from Primary Sources
List of Figures
Figure 1. Global PEGylated Protein Therapeutics Market Share by Type: 2020 VS 2026
Figure 2. Colony Stimulating Factor Features
Figure 3. Interferon Features
Figure 4. Erythropoietin (EPO) Features
Figure 5. Recombinant Factor VIII Features
Figure 6. Monoclonal Antibody Features
Figure 7. Enzyme Features
Figure 8. Others Features
Figure 9. Global PEGylated Protein Therapeutics Market Share by Application: 2020 VS 2026
Figure 10. Cancer Case Studies
Figure 11. Autoimmune Disease Case Studies
Figure 12. Hepatitis Case Studies
Figure 13. Multiple Sclerosis Case Studies
Figure 14. Hemophilia Case Studies
Figure 15. Gastrointestinal Disorder Case Studies
Figure 16. Others Case Studies
Figure 17. PEGylated Protein Therapeutics Report Years Considered
Figure 18. Global PEGylated Protein Therapeutics Market Size YoY Growth 2015-2026 (US$ Million)
Figure 19. Global PEGylated Protein Therapeutics Market Share by Regions: 2020 VS 2026
Figure 20. Global PEGylated Protein Therapeutics Market Share by Regions (2021-2026)
Figure 21. Porter's Five Forces Analysis
Figure 22. Global PEGylated Protein Therapeutics Market Share by Players in 2019
Figure 23. Global Top PEGylated Protein Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in PEGylated Protein Therapeutics as of 2019
Figure 24. The Top 10 and 5 Players Market Share by PEGylated Protein Therapeutics Revenue in 2019
Figure 25. North America PEGylated Protein Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Europe PEGylated Protein Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. China PEGylated Protein Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 28. Japan PEGylated Protein Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 29. Southeast Asia PEGylated Protein Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 30. India PEGylated Protein Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 31. Central & South America PEGylated Protein Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 32. Bottom-up and Top-down Approaches for This Report
Figure 33. Data Triangulation
Figure 34. Key Executives Interviewed
第VIII因子欠乏症治療の世界市場（～2026年） Factor VIII is an essential blood-clotting protein, which is also known as an antihemophilic factor. In individuals, factor VIII is encoded by F8 gene. Defects in F8 gene lead to hemophilia A, a recessive X-linked coagulation disorder. Factor VIII is generated in liver sinusoidal cells and endotheli…- 顆粒球マクロファージコロニー刺激因子の世界市場（～2026年） Market Analysis and Insights: Global Granulocyte Macrophage Colony Stimulating Factor Market The global Granulocyte Macrophage Colony Stimulating Factor market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Granulocyte Macro…
- PEG化医薬品の世界市場（～2026年） Market Analysis and Insights: Global PEGylated Drugs Market The global PEGylated Drugs market size is projected to reach US$ 7218.2 million by 2026, from US$ 7003.6 million in 2020, at a CAGR of 2.8%% during 2021-2026. Global PEGylated Drugs Scope and Market Size PEGylated Drugs market is segmented …
- 血友病A・B組換え因子補充療法の世界市場（～2026年） Haemophilia is a group of inherited genetic disorders which causes abnormal or exaggerated bleeding. It impairs the normal mechanism of blood clotting after an injury. Internal bleeding inside the joint or inside brain is commonly seen in the patients with severe to moderate haemophilia. Its symptom…
- 組換えタンパク質の世界市場（～2026年） Market Analysis and Insights: Global Recombinant Protein Market The global Recombinant Protein market size is projected to reach US$ 665.5 million by 2026, from US$ 612 million in 2020, at a CAGR of 8.1%% during 2021-2026. Global Recombinant Protein Scope and Market Size Recombinant Protein market i…